Juvenile myelomonocytic leukemia

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

Section editor
David Noyd, MD, MPH
University of Oklahoma
Oklahoma City, OK
1 regimens on this page
1 variants on this page

First-line therapy

Azacitidine monotherapy


Study Years of enrollment Evidence
Niemeyer et al. 2021 (AZA-JMML-001) 2015-2017 Phase 2, <20 pts (RT)


28-day cycles


  1. AZA-JMML-001: Niemeyer CM, Flotho C, Lipka DB, Starý J, Rössig C, Baruchel A, Klingebiel T, Micalizzi C, Michel G, Nysom K, Rives S, Schmugge Liner M, Zecca M, Schönung M, Baumann I, Nöllke P, Benettaib B, Biserna N, Poon J, Simcock M, Patturajan M, Menezes D, Gaudy A, van den Heuvel-Eibrink MM, Locatelli F. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. Blood Adv. 2021 Jul 27;5(14):2901-2908. link to original article link to PMC article PubMed NCT02447666